!!Zhao-Qi Wang - Curriculum Vitae
\\
__EDUCATION:__\\
\\
1978, Oct-1982, Jul: Bachelor of Science (B.Sc.) (Zoology)\\
  Department of Biology, \\
  Shandong University\\
  Jinan, Shandong Province, People’s Republic of China\\
\\
1982, Sep-1985, Oct: Master of Science (M.Sc.) (Cell Biology)\\
  Department of Cell Biology \\
  Peking Union Medical College (PUMC)\\
  Beijing, People’s Republic of China\\
\\
1990, Sep-1993, Jun: Ph.D. (Biochemistry)\\
  Biochemistry Institute, Innsbruck University\\
  Innsbruck, Austria
\\
\\
__POSITIONS:__\\
\\
1985 Oct-1988 July: Research Associate, Lecturer \\
  Institute of Basic Medical Sciences \\
  Peking Union Medical College (PUMC) \\
  Chinese Academy of Medical Sciences (CAMS) \\
  5 Dong Dan San Tiao, Beijing, People’s Republic of China\\
\\
1988 (Jul-Oct):  Postdoctoral fellow \\
  Laboratory of Dr Erwin F. Wagner\\
  European Molecular Biology Laboratory (EMBL)\\
  Meyerhof straße 1\\
  D-6900 Heidelberg, Germany\\
\\
1988 Oct-1993 July: Postdoctoral fellow \\
  Laboratory of Dr Erwin F. Wagner\\
  Research Institute of Molecular Pathology (I.M.P.) \\
  Dr. Bohr-Gasse 7, A-1030, Vienna, Austria\\
\\
1993 Jul-1995 Oct: Staff Scientist \\
  Laboratory of Dr Erwin F. Wagner\\
  Research Institute of Molecular Pathology (I.M.P.)\\
  Dr. Bohr-Gasse 7, A-1030, Vienna, Austria\\
\\
1995 Oct-1997 Jan: Scientist \\
  Research Institute of Molecular Pathology (I.M.P.)\\
  Dr. Bohr-Gasse 7, A-1030, Vienna, Austria\\
\\
1997 Feb-2006 Jan: Unit Chief/Group Head \\
  Gene-Environment Interactions \\
  International Agency for Research on Cancer (IARC)\\
  150, cours Albert Thomas, 69008 Lyon, France\\
\\
2006 Jan-present:  a. Full Professor\\
  Faculty of Biology-Pharmacy,\\
  Friedrich-Schiller-University Jena\\
  b. Senior Group Leader\\
  Leibniz Institute for Age Research\\
  —Fritz Lipmann Institute (FLI)\\
  Beutenbergstrass 11, 07745 Jena, Germany
\\
\\
__PROFESSIONAL ACTIVITIES:__
\\
#Honorary professor, Jinan University, Guangzhou, China\\
#Visiting professor, Basic Institute of Medical Sciences, Peking Union Medical Collage/Chinese Academy of Medical Sciences, Beijing, China\\
#Overseas’ Representative of Chinese Anti-Cancer Association (CACA, UICC Branch)\\
#International Expert for Chinese Academy of Sciences (CAS),  China\\
#Scientific Responsible Supervisor of the Animal Facility of IARC, Lyon, France (1997-2006)\\
#Scientific Responsible Supervisor of the Animal Facility of FLI, Jena, Germany (2006-present)\\
#Member of Scientific Council, FLI, Jena, Germany (2007-2010)
\\
__RESEARCH ACTIVITIES__\\
\\
1982-1988:  Establishment of oocyte microinjection and transgenic mouse technologies to study the regulatory effect of cytoplasmic factors on the functional activity of tumor cell nuclei.\\
\\
1988-1996:  Establishment and refining of ES cell and gene knockout technologies for functional analysis of AP-1 transcription factors in tumorigenesis and mouse development. Studies on the role of insulin-like growth factor type 2/mannose 6-phosphate receptor (Igf2/Mpr), Pax5 and AMOG in mouse development and functional study of poly(ADP-ribose) polymerase (ADPRT, PARP-1) using molecular tools and knockout mice.\\
\\
1997-2006: Novel mouse models and rodent assays for human carcinogenesis\\
Development of the "humanized" p53 mouse model by the knock-in technique for molecular epidemiological and preventive studies of cancer development and testing carcinogen-induced mutation spectra of the human p53 gene in these mutant mice. Generation of mouse models for NBS, X-linked lymphoproliferative disease gene (XLP), Multiple Endocrine Neoplasia Type 1 gene (MEN1), Li-Fraumeni sydrome (p53) and Fanconi Anemia gene (FA) for studying the molecular mechanism in these diseases and their susceptibility to cancer. \\
\\
1997-present: Homeostasis of poly-ADP-ribosylation in patho-physiological processes\\
 Study of PARP-1 function in regulating apoptosis and necrosis, genomic stability, inflammation and transcription regulations. Involvement of the homeostasis of poly-ADP-ribosylation in pathogenesis using animal models in which either the synthesising (PARP-1) or degrading (PARG) enzymes are genetically modified or inactivated. Functional dissection of poly(ADP-ribose) metabolism in cell cycle control and DNA repair.\\
\\
Chromatin remodelling, cell cycle control and DNA damage response\\
Investigation of the involvement of histone acetyltransferase cofactor TRRAP in cell cycle control, DNA damage response and neurogenesis using mouse and cellular models.\\
\\
DNA damage response and genomic stability \\
Elucidation of the molecule mechanisms of DNA repair, damage signaling, chromosome stability, and tumorigenesis. Functional study of genes that are responsible for DNA damage response and repair, such as PARP-1, p53, DNA-PK, Ku80, the Fanconi Anemia gene (FA) and Nijmegen Breakage Syndrome (NBS; mutated in NBS1), by generating and characterizing mouse models in which one or more of these molecules are mutated by gene targeting and transgenic approaches. \\
\\
DNA damage response in mouse and cellular models\\
Study of DNA damage response mediated by NBS1, ATM, ATR and TopBP1 by generating and characterizing the knockout and knockin animal and cellular models. Specific inactivation of these genes in the central nervous system (CNS), lymphoid cells as well as in the stem cell compartment.\\
\\
Neuronal disease models\\
Primary microcephaly genes (MCPH) and DNA damage response genes (ATR, MRE11 and NBS1) are important in maintaining of the brain size. MCPH genes encode centrosome proteins and the function of these genes is hypothesized to regulate determination of cell fate during neuroprogenitor division. We use transgenic and knockout mouse models to analyse the function of these genes.
\\
\\
__RESEARCH GRANTS__
\\
#Association for International Cancer Research (AICR, UK): "Functional study of homeostasis of poly(ADP-ribosyl)ation: Analyses of poly(ADP-ribose) glycohydrolase (PARG) deficient mice", 261,300 £ (April 1999-March 2002)\\
#Association pour la Recherche sur le Cancer (ARC, France): "The MEN1 gene: establishment of animal models by a novel conditional approach", 300,000 FrF (October 1998-September 2000) (co-applicant)\\
#National Institute of Health, USA: "Mutations in Human p53 Sequences of a p53 Knock-in Mouse", 282,000 $ (July 1999-June 2002) (co-applicant)\\
#Region Rhône-Alpes: "Analysis of poly(adp-ribose) glycohydrolase deficient mice", 240,000 FrF (January 2000-December 2001)\\
#ARC: "Genetic and functional studies of the role of the SH2D1A and SLAM genes in X-linked lymphoproliferative disease and in other Epstein-Barr virus-associated diseases", 300,000 FrF (January 2000-December 2001) (co-applicant)\\
#AICR: "Genetic and functional studies of the role of the SH2D1A and SLAM genes in X-linked lymphoproliferative disease and in other Epstein-Barr virus-associated diseases", 306,450 £ (April 2000-March 2003) (co-applicant)\\
#ARC: "Functional study of Multiple Endocrine Neoplasia-Type 1 gene: establishment of a MEN1 mutant mouse model using conditional targeting approach, and analyses of the biological consequences related to the inactivation of this putative tumor suppressor", 800,000 FrF (October 2000 - September 2002) (co-applicant)\\
#AICR: "Functional study of Multiple Endocrine Neoplasia-Type 1 gene: Establishment of MEN1 deficient cell lines and mouse disease models using gene targeting approach", 144,000 £ (April 2001 - March 2004) (co-applicant)\\
#ARC: "Involvement of poly(ADP-ribose) polymerase (PARP) in mammary gland carcinoma formation", 300,000 FrF (April 2001 - March 2003).\\
#ARC: "Role of poly(ADP-ribose) polymerase (PARP-1) in chromosomal recombination, genomic stability and human cancer", 25,000 € (April 2003 - March 2004).\\
#ARC: “Role of PARP-1 in genomic stability and tumorigenesis”, 40,000 € (January 2004 - December 2005).\\
#Association for International Cancer Research (AICR, UK): “The molecular and genetic dissection of DNA damage response pathways in vivo”139,500 £ (October 2005 - September 2008)\\
#Fundacio La Maratóde TV3 Spain: “Do cancer cells mimic the strategy of embryonic stem cells in order to be immortalized?” 125,000 €(April 2007 - March 2010)\\
#German-Israeli Foundation (GIF): “Ataxia telangiectasia: the role of the DNA damage response in neuronal attrition” 197,575 € (January 2008-December 2010)\\
#German Academic Exchange Service (DAAD) - Institut National du Cancer France (INCa): “ATM genotype dependent modulation of DNA damage responses to ionising radiation” 50,000€ (September 2007-August 2009)\\
#Deutschen Forschungsgemeinschaft (DFG): “The molecular and genetic dissection of DNA damage response using cellular and animal models” 290,000€ (August 2008 - September 2011)\\
#The Dieter-Platt-Stiftung: “DNA Damage Response (DDR) in Neuro(de)generation” 12,000€ (December 2009 - November 2010)\\
#Deutschen Forschungsgemeinschaft (DFG): “The Functional Study of The DNA Damage Response Molecule MCPH1 in Neurogenesis Using Cellular and Animal Model” 400,000€ (February 2010 - January 2012)\\
#Deutschen Forschungsgemeinschaft (DFG): “The Functional Study of The DNA Damage Response Molecule MCPH1 in Neurogenesis Using Cellular and Animal Model” 403,224€ (February 2010 - January 2013)\\
#Deutschen Forschungsgemeinschaft (DFG): “Functional Analysis of Poly(ADP-ribose) Binding by Cell Cycle Regulator Chk1” 288,960€ (August 201 - July 2014)\\
#Deutschen Forschungsgemeinschaft (DFG)-GRK1715: “Molecular Signatures of Adaptive Stress Responses” 222,300€ (January 2012 – September 2015)